Several candidate antigens are under investigation for their potential in glioma therapy: IL13Rα2 is highly expressed in WHO grade 4 gliomas; epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in gliomas, including glioblastoma (GBM); human epidermal growth factor receptor 2 (HER2) is overexpressed in various CNS tumors; GD2 is highly expressed in pediatric gliomas; and B7H3 is highly expressed in both pediatric and adult gliomas [91]. Here, ERBB2 is linked to central nervous system neoplasm.